

## Lung Cancer Treatments (NSCLC)

Reference Number: RDF1709-23

Date of Response: 16/08/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

*Dear Royal Devon University Healthcare NHS Foundation Trust,*

*I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:*

*1. How many patients has your Trust treated in the past 3 months for:*

Question	Trust Total
• Non-small cell lung cancer (NSCLC) - total number of patients treated for NSCLC using any therapy.	19
• Non-small cell lung cancer (NSCLC) - surgical treatment	* ≤5
• Non-small cell lung cancer (NSCLC) - radiotherapy	31
• Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT)	125

*2. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:*

Regimen	Trust Total
• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	11
• Amivantamab	0
• Atezolizumab monotherapy	* ≤5
• Atezolizumab with chemotherapy	* ≤5
• Dabrafenib + Trametinib	* ≤5
• Durvalumab	8
• Gemcitabine	0
• Nintedanib + Docetaxel	* ≤5
• Nivolumab	0
• Osimertinib	27
• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	* ≤5
• Paclitaxel	0

• Pembrolizumab monotherapy	29
• Pembrolizumab with chemotherapy	11
• Pemetrexed with carboplatin/cisplatin	* ≤5
• RET Inhibitors (Pralsetinib, Selpercatinib)	0
• Sotorasib	* ≤5
• Tepotinib	* ≤5
• Vinorelbine monotherapy or combination with Carboplatin/Cisplatin	* ≤5
• Other active systemic anti-cancer therapy [please state*]	17
• Palliative care only	12

\* ≤5 Exemption - Section 40

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

*Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment **with** Nivolumab? Nil.*